Document is current
Any future updates will be listed below
-
Authors
Gao, Xiangyu https://orcid.org/0000-0002-1697-1157
Ji, Ke
Jia, Yongning https://orcid.org/0000-0002-9215-7907
Shan, Fei https://orcid.org/0000-0002-4792-3385
Chen, Ye
Xu, Nong
Jia, Ziyu
Liu, Tianshu https://orcid.org/0000-0002-8604-6311
Yang, Nong
Zhong, Haijun
Li, Changzheng
Guo, Zengqing
Fan, Qingxia
Lin, Xiaoyan
Zhang, Yan
Ren, Hui
Yang, Hongxia
Yao, Zhifang
Liu, Wei
Wang, Zhongmin Maxwell https://orcid.org/0000-0002-1683-5147
Li, Baiyong
Xia, Michelle
Shen, Lin https://orcid.org/0000-0003-1134-2922
Li, Ziyu https://orcid.org/0000-0001-5580-4979
Ji, Jiafu https://orcid.org/0000-0001-6878-5543
- License Information
-
More Information
Article History
Received: 15 May 2023
Accepted: 17 April 2024
First Online: 22 May 2024
Competing interests
: L.S. reports consulting fees from Mingji Biopharmaceutical, Haichuang Pharmaceutical and Herbour Biomed; grants or contracts from Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), ALPHAMAB ONCOLOGY, Yaojie Ankang (Nanjing) Technology, Beigene, Qiyu Biotechnology (Shanghai) and BriSTAR Immunotech; and participation on a data safety monitoring board or advisory board for MSD, Merk, Bristol Myers Squibb, Boehringer Ingelheim, Sanofi, Roche, SERVIER and AstraZeneca. Z.Y., W.L., Z.M.W., B.L. and M.X. are employees of Akeso Biopharma. The remaining authors declare no competing interests.
